LAVA Therapeutics NV at HC Wainwright Immune Cell Engager Virtual Conference Transcript

Aug 17, 2023 / 02:00PM GMT
Arthur He - H.C. Wainwright & Co., LLC - Analyst

Greetings, everyone. My name is Arthur He, a senior biotech analyst at H.C. Wainwright. Thanks for joining us to have a conversation with the management of LAVA Therapeutics: Mr. Steve Hurly, their CEO; and Mr. Fred Powell, the Chief Financial Officer; and Dr. Charles Morris, the Chief Medical Officer.

LAVA Therapeutics is a clinical-stage biotechnology company focused on developing gamma bodies to harness Gammabody to harness gamma-delta T cells for cancer treatment. The company currently has one drug in clinical development and several preclinical candidates.

To discuss the company's development strategy in 2023 and beyond, I welcome Steve, Fred, and Charlie to this fireside chat. Good morning, Steve, Fred, and Charlie.

Steve Hurly - LAVA Therapeutics, N.V. - CEO & Board Director

Good morning, Arthur. Thanks for having us.

Fred Powell - LAVA Therapeutics, N.V. - CFO

Good morning.

Charles Morris - LAVA

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot